India Remains one of the top priority on USTR's 'Priority Watch List’ again in 2020.

Washington DC

Oct 2, 2020


India has yet again failed to address the US' concerns regarding the enforcement of actions under Section 301 of the Trade Act or pursuant to World Trade Organisation or other trade agreement dispute settlement procedures, necessary to combat unfair trade practices and to ensure that trading partners follow through with their international commitments.
The report also mentioned high customs duties on medical devices and Information and Communications Technology. These goods categories were have been persistent challenges in trade talks between the two countries last year — the language used in the 2020 report in this context is the same as in the 2019 report.
The ongoing concerns include the difficulty of investors to receive and maintain patents in the country particularly for pharmaceuticals, insufficient enforcement actions, copyright policies that do not properly incentivise the creation and commercialisation of content, and an outdated and insufficient trade secrets legal framework. Furthermore, the failure of the country to establish an effective system for protecting against the unfair commercial use, as well as the unauthorised disclosure, of undisclosed test or other data generated to obtain marketing approval for certain agricultural chemical products still remain the secondary concerns that require immediate solution